In this article, we will take a look at the 5 Healthcare Stocks with Highest Dividends. For deeper discussion and analysis, have a look at the 1o Healthcare Stocks with Highest Dividends.
5. Amgen Inc. (NASDAQ:AMGN)
Dividend Yield as of April 15: 2.89%
On April 13, UBS lifted its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $400 from $390. It reiterated a Buy rating on the shares. The revision came as part of a broader Q1 preview across the pharmaceuticals and biotechnology group.
On April 8, Truist also updated its view on the company. It boosted its price target to $325 from $319 and maintained a Hold rating, as part of a wider preview of Q1 earnings in biotech. The firm said that reactivity to regulatory and policy shifts across the sector has started to ease. It also pointed to a recent pickup in deal activity, which could build momentum through the rest of the year and into the mid-term period. For Amgen, Truist made a few specific adjustments. It increased its long-term penetration assumptions for Krystexxa, citing stronger patent protection that now extends into 2040. It also raised the probability of success for MariTide, reflecting greater confidence in its commercially viable profile in obesity.
Amgen Inc. (NASDAQ:AMGN) is a biotechnology company focused on discovering, developing, manufacturing, and delivering medicines for serious diseases. The company targets areas with high unmet medical needs and uses its expertise to develop treatments aimed at improving patient outcomes. It operates within the human therapeutics segment.
4. Medtronic plc (NYSE:MDT)
Dividend Yield as of April 15: 3.26%
On April 15, Truist analyst Richard Newitter lowered the firm’s price target on Medtronic plc (NYSE:MDT) to $95 from $103 and kept a Hold rating on the shares. The update came as part of a broader Q1 preview for MedTech.The analyst said Q1 performance is expected to come in line with, or slightly better than, what current investor sentiment suggests around volumes. There is some caution in the market, but the underlying expectations appear more stable. Truist also noted that the stock’s discount could narrow. The reasoning is straightforward. The company is now one quarter closer to potential revenue accelerants. At the same time, it will need to show faster revenue and EPS growth to support higher valuation multiples over the long term.
On April 13, Mizuho also updated its view on the company. It lowered its price target on Medtronic to $120 from $125 and kept an Outperform rating on the shares. The firm adjusted estimates and targets across several names in medical devices and diagnostics ahead of Q1 earnings.
Medtronic plc (NYSE:MDT) is based in Ireland and provides healthcare technology solutions. Its business is organized across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.
3. CVS Health Corporation (NYSE:CVS)
Dividend Yield as of April 15: 3.55%
On April 15, Baird raised its price recommendation on CVS Health Corporation (NYSE:CVS) to $94 from $92. It reiterated an Outperform rating on the shares. The firm updated its model as it became more constructive on the stock.
During the Q4 2025 earnings call, CEO David Joyner said 2025 had been a meaningful year of progress for CVS Health. He pointed to the company’s ongoing effort to simplify healthcare while improving affordability and access. He referred to fourth-quarter results, noting adjusted operating income of $2.6 billion and adjusted EPS of $1.09. He also reiterated the company’s full-year 2026 adjusted EPS guidance, which remains in the range of $7 to $7.20.For the full year, Joyner reported adjusted EPS of $6.75 and operating cash flow of $10.6B. Both came in ahead of the company’s initial expectations.
Within the Aetna segment, he said adjusted operating income improved by more than $2.6 billion year over year. He added that the company refreshed its leadership team, worked on improving its culture, and strengthened key differentiators, including capabilities supporting its leading Stars position among national payers.
CVS Health Corporation (NYSE:CVS) operates as a health solutions company. Its segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness, and Corporate/Other. The Health Care Benefits segment provides a range of traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans, PDPs, and Medicaid health care management services.
2. Embecta Corp. (NASDAQ:EMBC)
Dividend Yield as of April 15: 6.24%
On April 13, Mizuho lowered its price recommendation on Embecta Corp. (NASDAQ:EMBC) to $12 from $14. It reiterated a Neutral rating on the shares. The change came as the firm adjusted estimates and targets across several medical devices and diagnostics names ahead of Q1 earnings.
The same day, BTIG also updated its view. It lowered its price target on Embecta to $22 from $25 while maintaining a Buy rating, as part of a broader research note on medical technology. BTIG said it is revising its models following the CMS proposed rule for the FY27 inpatient prospective payment system. The update includes early commentary and decisions tied to new technology add-on payments, according to the analyst.
Earlier in March, Embecta said it had reached a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based company known for its work in medical devices and drug-delivery technologies. Under the deal, Embecta will pay £100 million in cash at closing, with the final amount subject to customary adjustments. The agreement also includes up to £50 million in additional payments, tied to how the Aidaptus next-generation auto-injector platform performs over the three years after closing.
The company’s Board of Directors approved the transaction unanimously. It is expected to close in Embecta’s fiscal third quarter of 2026, pending regulatory approvals and other standard conditions.
Embecta Corp. (NASDAQ:EMBC) operates as a global diabetes care company, focused on supporting people living with diabetes. Its portfolio includes pen needles, syringes, and safety injection devices, along with a digital application designed to help patients manage their condition.
1. Spok Holdings, Inc. (NASDAQ:SPOK)
Dividend Yield as of April 15: 11.29%
On April 14, Spok Holdings, Inc. (NASDAQ:SPOK) announced it is reshaping parts of the business to cut costs and tighten its focus, particularly across its go-to-market teams. The idea is straightforward. Free up resources now so the company can keep investing in its Care Connect Suite and push further into artificial intelligence, while still returning cash to shareholders.
As part of that effort, management plans to simplify the leadership structure and reduce the workforce by about 10%. The company expects this move to lower headcount-related costs, excluding stock-based compensation, along with other operating expenses by more than $6.0 million a year. There is a near-term cost to get there. Spok estimates restructuring charges of roughly $1.6 million to $2.0 million, mostly hitting in the second and third quarters of 2026. These costs are largely tied to one-time items like employee benefits and severance. The company expects most of this process to wrap up by the third quarter.
That said, these figures rely on internal assumptions, and actual results could end up looking different. Management also noted that unexpected developments during execution could lead to additional charges or cash outflows that are not part of the current estimate. For reporting purposes, the company plans to exclude these restructuring costs from its non-GAAP metrics, including Adjusted EBITDA and adjusted operating expenses.
Spok Holdings, Inc. (NASDAQ:SPOK) operates through its wholly owned subsidiary, Spok, Inc., focusing on healthcare communications. Its offerings center on clinical communication and collaboration tools, including call center solutions, alerting and notification systems, wireless messaging, mobile communication platforms, and public safety solutions.
While we acknowledge the potential of SPOK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SPOK and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
